Best Peptide Protocols
    ResearchMay 28, 202612 min

    Semax vs Selank: The Cognitive Peptide Comparison

    Both are Russian-developed nootropic peptides with clinical data behind them — but they work through entirely different mechanisms. A complete research comparison of Semax and Selank.

    Two Peptides, Two Mechanisms

    Semax and Selank are the two most extensively studied nootropic peptides with actual clinical data — a distinction that separates them from the majority of cognitive compounds discussed in the research space. Both originated from Soviet-era and Russian neuropharmacological programs, both are approved in Russia for clinical indications, and both have attracted renewed global research interest.

    But they are mechanistically distinct, produce different subjective and objective effects, and serve different research purposes.

    Semax: The Pro-Cognitive, BDNF-Upregulating Peptide

    Structure and Origin

    Semax is a synthetic heptapeptide analog of ACTH(4–10) — the Met-Glu-His-Phe-Pro-Gly-Pro sequence — developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s. A Pro-Gly-Pro sequence was added to improve metabolic stability and extend the half-life of the active fragment.

    Primary Mechanism

    Semax's most replicated effect in animal research is a rapid, substantial increase in BDNF (brain-derived neurotrophic factor) mRNA in the hippocampus. In rodent studies, a single intranasal dose produced:

  1. Tripling of hippocampal BDNF mRNA within hours
  2. Increased TrkB (BDNF receptor) phosphorylation
  3. Upregulation of NGF (nerve growth factor) expression

    4. This BDNF mechanism drives synaptic plasticity, neuronal resilience, and cognitive performance across learning-dependent tasks. Semax also modulates dopaminergic and serotonergic neurotransmission — enhancing dopamine and serotonin turnover in prefrontal and limbic circuits, producing the activating, cognitively sharpening effect frequently reported.

    Clinical Research

    Semax has received the most rigorous clinical evaluation of any nootropic peptide outside the Western trial framework:

  4. Ischemic stroke: Multiple Russian controlled trials showed improved neurological recovery outcomes when Semax was administered within the therapeutic window
  5. Attention and cognition: Clinical studies in children with attention difficulties showed improvements in cognitive performance metrics
  6. Glaucoma: A 2020 RCT (n=56) demonstrated improved visual function in patients with glaucoma and optic nerve atrophy

    7. A 2025 preclinical study in the Alzheimer's model (APPswe/PS1dE9/Blg transgenic mice) found that both Semax and a derivative improved cognitive function — extending the neuroprotective picture into neurodegeneration research (published in Acta Naturae, with a 2026 follow-up study, PMID 41479572, examining correction of pathological impairments).

    A separate 2026 study (Wang et al., Neurotherapeutics) showed Semax promotes deubiquitination and functional recovery after spinal cord injury in female mice — a notable finding for neuroregenerative research.

    Standard Research Protocol

  7. Route: Intranasal (most studied, preferred); subcutaneous also used
  8. Vial format: 5 mg lyophilized vial, reconstituted in 2 mL → 2.5 mg/mL
  9. Research dose range: 200 mcg – 1 mg per dose, 1–2× daily
  10. Cycle length: 2–4 weeks on; 2–4 weeks off

    11. Selank: The Anxiolytic, Stress-Modulating Peptide

    Structure and Origin

    Selank is a synthetic heptapeptide analog of tuftsin — the Thr-Lys-Pro-Arg-Pro-Gly-Pro sequence — developed by the Institute of Molecular Genetics in the 1990s. It was designed to retain tuftsin's immunomodulatory and anxiolytic properties while improving stability.

    Primary Mechanism

    Selank operates through GABAergic and serotonergic pathways:

  11. GABAergic modulation: Potentiates GABA-A receptor activity, producing anxiolytic effects without the sedation, dependence, or withdrawal associated with benzodiazepines
  12. Enkephalin stabilization: Inhibits enzymes that break down enkephalins (endogenous opioid peptides), extending their anxiolytic and mood-stabilizing activity
  13. Serotonin transporter modulation: A 2025 preclinical study demonstrated that Selank reduced serotonin transporter (SERT) expression in hippocampal tissue after 14 days of administration, effectively raising synaptic serotonin availability without direct receptor agonism
  14. BDNF upregulation: Like Semax, Selank increases BDNF expression, though to a lesser degree and through different upstream pathways

    15. Clinical Research

    Selank completed Phase III clinical trials in Russia for anxiety-related indications — a higher evidentiary standard than any Western nootropic peptide. This data supports its approval in Russia as an anxiolytic medication.

    Key documented effects:

  15. Reduced anxiety with preserved cognitive performance (distinct from benzodiazepines, which impair cognition)
  16. No sedation, no dependency, no withdrawal
  17. Immunomodulatory activity — enhancement of interferon expression and T-helper cell activity

    18. Standard Research Protocol

  18. Route: Intranasal (primary studied route); subcutaneous also used
  19. Vial format: 5 mg lyophilized vial, reconstituted in 2 mL → 2.5 mg/mL
  20. Research dose range: 250 mcg – 750 mcg per dose, 1–2× daily
  21. Cycle length: 2–4 weeks on; 1–2 weeks off (shorter cycle often used given mild profile)

    22. Side-by-Side Comparison

    FeatureSemaxSelank
    Primary mechanismBDNF upregulation, dopaminergicGABAergic, serotonergic
    Primary effectCognitive activation, focus, driveAnxiety reduction, stress resilience
    SedationNo (activating)No (non-sedating anxiolytic)
    Clinical dataStroke, cognition, glaucomaPhase III anxiety trials
    Best fitFocus deficit, brain fog, neuroprotectionAnxiety, stress, cognitive clarity under pressure
    Typical onset30–60 min intranasal30–60 min intranasal
    Cycle length2–4 weeks2–4 weeks
    CombinationOften stacked with SelankOften stacked with Semax

    Combining Semax and Selank

    The Semax + Selank combination is one of the most frequently investigated nootropic peptide pairings in preclinical research. The rationale is mechanistic complementarity:

  22. Semax provides the pro-cognitive, activating, BDNF-driven enhancement
  23. Selank provides the anxiolytic, GABAergic stabilization that can offset any activating overstimulation

    24. In research settings, this combination has been studied for:

  24. Additive effects on BDNF expression (each compound upregulates via different pathways)
  25. Complementary action on neuroinflammation markers
  26. Potential synergy in stress-induced cognitive impairment models

    27. Both peptides share the intranasal route as their primary delivery method, making co-administration straightforward in research protocols.

    2026 Regulatory Update

    On February 27, 2026, HHS Secretary Kennedy announced that Semax and Selank are among the peptides expected to move from FDA Category 2 to Category 1 — restoring the 503A compounding pharmacy pathway.

    This means:

  27. Licensed physicians can prescribe both compounds
  28. Licensed compounding pharmacies can legally prepare them
  29. Access through a regulated, supervised medical pathway becomes available

    30. Until the formal rulemaking is finalized, both remain in Category 2. The trajectory toward legitimate supervised access is significant for researchers who have been using grey-market sources.

    Differentiating Use Cases

    Choose Semax when the research focus is:

  30. Cognitive performance — working memory, executive function, focus
  31. Neuroprotection following injury or ischemic events
  32. BDNF-dependent neuroplasticity (learning models)
  33. Brain fog, motivational deficit, cognitive flatness

    34. Choose Selank when the research focus is:

  34. Anxiety and stress response modulation
  35. HPA axis regulation
  36. Cognitive performance under acute stress conditions
  37. Sleep quality alongside anxiolysis
  38. Immune modulation concurrent with cognitive support

    39. Choose both when the research focus is:

  39. Comprehensive cognitive and stress resilience protocol
  40. BDNF maximization through dual pathways
  41. Models of chronic stress with cognitive impairment

    42. Important Note

    This article is for educational and research reference purposes only. Semax and Selank are not FDA-approved in the United States and are classified as Category 2 bulk drug substances pending reclassification. All information presented here reflects the current research literature and is not medical advice.